TABLE 2

Cell cycle modulation and apoptotic index

Cells and Treatmenta
G1 Phase
S Phase
G2/M Phase
Apoptotic Index
%
A549
Control 59.9 ± 2.4 21.1 ± 1.4 18.9 ± 1.4 1.2 ± 0.2
Erlotinib (E) 69.2 ± 2.0 18.2 ± 1.5 12.5 ± 2.3 4.5 ± 0.5*
Pemetrexed (P) 40.5 ± 5.0 37.0 ± 2.2 22.5 ± 1.4 9.2 ± 0.2*
E + P (72 h) 40.9 ± 1.7 39.1 ± 1.8 19.9 ± 1.7 11.8 ± 0.6*
E + P (24 h)-E (48 h) 34.0 ± 1.2 37.4 ± 3.2 28.6 ± 2.0 16.7 ± 2.2**
SW1573
Control 47.2 ± 4.0 24.6 ± 2.3 28.2 ± 1.9 0.8 ± 0.2
Erlotinib (E) 55.0 ± 6.6 23.1 ± 9.0 21.9 ± 2.2 4.8 ± 1.0*
Pemetrexed (P) 32.6 ± 1.8 39.1 ± 2.1 28.2 ± 0.2 10.8 ± 0.6*
E + P (72 h) 34.1 ± 5.7 36.6 ± 4.0 29.3 ± 1.8 13.2 ± 1.9*
E + P (24 h)-E (48 h) 33.8 ± 3.7 33.2 ± 0.1 33.0 ± 3.6 15.8 ± 1.9**
H460
Control 41.8 ± 3.0 25.0 ± 2.0 33.2 ± 1.3 1.3 ± 0.3
Erlotinib (E) 57.7 ± 3.2 19.2 ± 3.7 23.1 ± 3.7 3.5 ± 1.0*
Pemetrexed (P) 28.0 ± 3.9 34.6 ± 2.9 37.4 ± 2.2 6.2 ± 0.8*
E + P (72 h) 30.1 ± 3.5 35.3 ± 2.8 34.6 ± 1.8 9.7 ± 0.9*
E + P (24 h)-E (48 h) 27.6 ± 0.1 34.8 ± 0.5 37.6 ± 0.5 16.2 ± 2.8**
H292
Control 46.8 ± 2.2 24.7 ± 2.2 28.5 ± 4.4 1.0 ± 0.3
Erlotinib (E) 62.7 ± 6.1 19.7 ± 1.9 17.6 ± 5.0 6.5 ± 1.0*
Pemetrexed (P) 34.7 ± 2.0 33.1 ± 1.6 32.1 ± 3.5 13.7 ± 1.0*
E + P (72 h) 35.0 ± 1.5 37.8 ± 1.3 27.2 ± 0.4 18.5 ± 0.3**
E + P (24 h)-E (48 h) 33.8 ± 2.6 32.7 ± 3.7 33.5 ± 6.3 21.2 ± 2.2**
H1650
Control 60.1 ± 2.1 24.2 ± 0.8 15.7 ± 1.3 1.2 ± 0.2
Erlotinib (E) 73.1 ± 1.4 18.9 ± 0.2 7.9 ± 1.3 8.0 ± 0.1*
Pemetrexed (P) 34.6 ± 5.1 47.5 ± 1.6 17.9 ± 3.5 10.7 ± 0.6*
E + P (72 h) 37.3 ± 6.5 51.3 ± 1.5 11.4 ± 5.0 19.3 ± 0.4**
E + P (24 h)-E (48 h) 43.5 ± 5.1 35.5 ± 7.5 21.0 ± 2.4 21.2 ± 0.4**
H1703
Control 47.5 ± 2.1 38.7 ± 2.8 13.8 ± 0.7 1.3 ± 0.2
Erlotinib (E) 58.8 ± 1.6 32.2 ± 1.1 9.0 ± 0.5 4.2 ± 0.6*
Pemetrexed (P) 40.2 ± 0.2 55.3 ± 0.7 4.4 ± 0.7 8.0 ± 0.5*
E + P (72 h) 31.6 ± 2.0 56.2 ± 3.3 12.2 ± 1.2 10.5 ± 1.3*
E + P (24 h)-E (48 h)
38.6 ± 1.7
46.1 ± 7.8
15.4 ± 6.0
13.2 ± 0.7**

  • ↵* P < 0.05 with respect to control cells.

  • ↵** P < 0.05 with respect to pemetrexed-treated cells.

  • ↵ a Cells were treated for 72 h to IC50 concentrations of the single drugs and of the combinations.